Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
Clinical trial NCT02970305 · COMPLETED
Trial details
- NCT number
- NCT02970305
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-11-04
- Primary completion
- 2019-10-16
- Enrollment
- 403
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.